SRPT241122C111000
- 1.55
- +0.35+29.17%
Sarepta Therapeutics Newsroom
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $197
J.P. Morgan Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Barclays Initiates Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $209
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $210
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Buy Rating on Sarepta Therapeutics: Confidence in Elevidys' Market Potential and Strategic Expansion
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and DocGo (DCGO)
Barclays Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $209
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $150 to $209
Sarepta Therapeutics: Strong Elevidys Sales Drive Buy Rating Amid Portfolio Optimism and Favorable Valuation
Sarepta Therapeutics Price Target Cut to $193.00/Share From $200.00 by Baird
Sarepta Therapeutics Is Maintained at Outperform by Baird
Evercore ISI Group Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $170
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $167 to $210
Sarepta Therapeutics Raised to Overweight From Neutral by Cantor Fitzgerald
RBC Capital Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)